{"id":4569,"date":"2020-07-02T10:35:19","date_gmt":"2020-07-02T09:35:19","guid":{"rendered":"https:\/\/www.cilcare.com\/?p=4569"},"modified":"2020-07-02T10:35:19","modified_gmt":"2020-07-02T09:35:19","slug":"how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.cilcare.com\/jp\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/","title":{"rendered":"How to assess drug candidates on tinnitus preclinical models for a successful transition to clinical trials ?"},"content":{"rendered":"<h2 class=\"null\"><span style=\"color: #008775;\"><strong>Sylvie Pucheu will be presenting a webinar on preclinical tinnitus models <\/strong><\/span><span style=\"color: #008775;\"><strong>on July 9, 2020<\/strong><\/span><span style=\"color: #008775;\"><strong>:<\/strong><\/span><\/h2>\n<p>&nbsp;<\/p>\n<h5>Tinnitus is one of the most common hearing disorders, for which there is no drug on the market yet.<\/h5>\n<h5>Dr Sylvie Pucheu, CSO &amp; co-founder of CILcare, will present two preclinical models developed by CILcare allowing to induce and detect Tinnitus: Salicylate-induced and Noise-induced models.<\/h5>\n<h5>Dr Pucheu will also provide insights on the readouts provided by these two models for a successful transition to clinical trials.<\/h5>\n<h5><span style=\"color: #000000;\">This webinar is co-organised with Neuroservices-Alliance, CILcare&#8217;s CRO partner specialized in CNS disorders.\u00a0<\/span><\/h5>\n<blockquote><p>Date: July 9<br \/>\nTime: 8PM CEST<\/p><\/blockquote>\n<p>&nbsp;<\/p>\n<h4><span style=\"color: #008775;\">Register for free:<\/span>\u00a0<a href=\"https:\/\/register.gotowebinar.com\/register\/9011353617612971535\" data-cke-saved-href=\"https:\/\/register.gotowebinar.com\/register\/9011353617612971535\">https:\/\/register.gotowebinar.com\/register\/9011353617612971535<\/a><\/h4>","protected":false},"excerpt":{"rendered":"<p>Sylvie Pucheu will be presenting a webinar on preclinical tinnitus models on July 9, 2020: &nbsp; Tinnitus is one of the most common hearing disorders, for which there is no drug on the market yet. Dr Sylvie Pucheu, CSO &amp; co-founder of CILcare, will present two preclinical models developed by CILcare allowing to induce and detect Tinnitus: Salicylate-induced and Noise-induced models. Dr Pucheu will also provide insights on the readouts provided by these two models for a successful transition to clinical trials. This webinar is co-organised with Neuroservices-Alliance, CILcare&#8217;s CRO partner specialized in CNS disorders.\u00a0 Date: July 9 Time: 8PM CEST &nbsp; Register for free:\u00a0https:\/\/register.gotowebinar.com\/register\/9011353617612971535<\/p>","protected":false},"author":3,"featured_media":4587,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,10],"tags":[],"class_list":["post-4569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classe","category-events","entry","has-media"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>How to assess drug candidates on tinnitus preclinical models for a successful transition to clinical trials ? - Cilcare<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cilcare.com\/jp\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to assess drug candidates on tinnitus preclinical models for a successful transition to clinical trials ? - Cilcare\" \/>\n<meta property=\"og:description\" content=\"Sylvie Pucheu will be presenting a webinar on preclinical tinnitus models on July 9, 2020: &nbsp; Tinnitus is one of the most common hearing disorders, for which there is no drug on the market yet. Dr Sylvie Pucheu, CSO &amp; co-founder of CILcare, will present two preclinical models developed by CILcare allowing to induce and detect Tinnitus: Salicylate-induced and Noise-induced models. Dr Pucheu will also provide insights on the readouts provided by these two models for a successful transition to clinical trials. This webinar is co-organised with Neuroservices-Alliance, CILcare&#8217;s CRO partner specialized in CNS disorders.\u00a0 Date: July 9 Time: 8PM CEST &nbsp; Register for free:\u00a0https:\/\/register.gotowebinar.com\/register\/9011353617612971535\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cilcare.com\/jp\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Cilcare\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-02T09:35:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2020\/07\/Tinnitus-Webinar-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1050\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"CILcare\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"CILcare\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/\",\"url\":\"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/\",\"name\":\"How to assess drug candidates on tinnitus preclinical models for a successful transition to clinical trials ? - Cilcare\",\"isPartOf\":{\"@id\":\"https:\/\/www.cilcare.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2020\/07\/Tinnitus-Webinar-2.png\",\"datePublished\":\"2020-07-02T09:35:19+00:00\",\"author\":{\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/71c4c9a5956da88e9a9de08ad23b27ac\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#primaryimage\",\"url\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2020\/07\/Tinnitus-Webinar-2.png\",\"contentUrl\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2020\/07\/Tinnitus-Webinar-2.png\",\"width\":1050,\"height\":600,\"caption\":\"Sylvie Pucheu present a tinnitus webinar\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cilcare.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to assess drug candidates on tinnitus preclinical models for a successful transition to clinical trials ?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cilcare.com\/#website\",\"url\":\"https:\/\/www.cilcare.com\/\",\"name\":\"Cilcare\",\"description\":\"Making hearing a priority\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cilcare.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/71c4c9a5956da88e9a9de08ad23b27ac\",\"name\":\"CILcare\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4bc8be812ab5693ac188aed8222fa384249de7201f47b7b8db392d1474d732de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4bc8be812ab5693ac188aed8222fa384249de7201f47b7b8db392d1474d732de?s=96&d=mm&r=g\",\"caption\":\"CILcare\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How to assess drug candidates on tinnitus preclinical models for a successful transition to clinical trials ? - Cilcare","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cilcare.com\/jp\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/","og_locale":"ja_JP","og_type":"article","og_title":"How to assess drug candidates on tinnitus preclinical models for a successful transition to clinical trials ? - Cilcare","og_description":"Sylvie Pucheu will be presenting a webinar on preclinical tinnitus models on July 9, 2020: &nbsp; Tinnitus is one of the most common hearing disorders, for which there is no drug on the market yet. Dr Sylvie Pucheu, CSO &amp; co-founder of CILcare, will present two preclinical models developed by CILcare allowing to induce and detect Tinnitus: Salicylate-induced and Noise-induced models. Dr Pucheu will also provide insights on the readouts provided by these two models for a successful transition to clinical trials. This webinar is co-organised with Neuroservices-Alliance, CILcare&#8217;s CRO partner specialized in CNS disorders.\u00a0 Date: July 9 Time: 8PM CEST &nbsp; Register for free:\u00a0https:\/\/register.gotowebinar.com\/register\/9011353617612971535","og_url":"https:\/\/www.cilcare.com\/jp\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/","og_site_name":"Cilcare","article_published_time":"2020-07-02T09:35:19+00:00","og_image":[{"width":1050,"height":600,"url":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2020\/07\/Tinnitus-Webinar-2.png","type":"image\/png"}],"author":"CILcare","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"CILcare","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"1\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/","url":"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/","name":"How to assess drug candidates on tinnitus preclinical models for a successful transition to clinical trials ? - Cilcare","isPartOf":{"@id":"https:\/\/www.cilcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2020\/07\/Tinnitus-Webinar-2.png","datePublished":"2020-07-02T09:35:19+00:00","author":{"@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/71c4c9a5956da88e9a9de08ad23b27ac"},"breadcrumb":{"@id":"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#primaryimage","url":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2020\/07\/Tinnitus-Webinar-2.png","contentUrl":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2020\/07\/Tinnitus-Webinar-2.png","width":1050,"height":600,"caption":"Sylvie Pucheu present a tinnitus webinar"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cilcare.com\/2020\/07\/02\/how-to-assess-drug-candidates-on-tinnitus-preclinical-models-for-a-successful-transition-to-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cilcare.com\/"},{"@type":"ListItem","position":2,"name":"How to assess drug candidates on tinnitus preclinical models for a successful transition to clinical trials ?"}]},{"@type":"WebSite","@id":"https:\/\/www.cilcare.com\/#website","url":"https:\/\/www.cilcare.com\/","name":"Cilcare","description":"Making hearing a priority","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cilcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/71c4c9a5956da88e9a9de08ad23b27ac","name":"CILcare","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4bc8be812ab5693ac188aed8222fa384249de7201f47b7b8db392d1474d732de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4bc8be812ab5693ac188aed8222fa384249de7201f47b7b8db392d1474d732de?s=96&d=mm&r=g","caption":"CILcare"}}]}},"_links":{"self":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/4569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/comments?post=4569"}],"version-history":[{"count":0,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/4569\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/media\/4587"}],"wp:attachment":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/media?parent=4569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/categories?post=4569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/tags?post=4569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}